Adma Biologics Inc (ADMA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Adma Biologics Inc   (NASDAQ: ADMA)


Adma Biologics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Adma Biologics Inc's ROI in the second quarter of 2026?
Adma Biologics Inc achieved a return on average invested assets (ROI) of 28.94 % in its second quarter of 2026, this is above ADMA's average return on investment of -48.57%.
Adma Biologics Inc invested over the 12 months ending in its second quarter of 2026 $584 million

ROI decreased relative to the period ending Mar 31 2026, due to the decline in net income.

Within the Healthcare sector 38 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 175, from total ROI ranking in the first quarter of 2026 at 207.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 37.25 % 41.56 % 49.61 % 55.23 % 45.25 %
Y / Y Net Income Change TTM -19.13 % -20.03 % -18.31 % 208.14 % 551.64 %
Investment (TTM) in Millions 643 592 588 513 485
Return On Investment (TTM) 28.94 % 30.38 % 28.75 % 44.57 % 49.11 %
ADMA's Overall Ranking # 175 # 207 # 92 # 65 #
Seq. Investment Change TTM 7.25 % 6.52 % 8.74 % 10.48 % 10.62 %
Seq. Net Income Change TTM 2.18 % 12.54 % -29.85 % 0.25 % 1.04 %
Net Income (TTM) in Millions 169 165 147 209 209

ADMA Company Profile >> Back to ADMA Roi Comparisons >> See Annual ADMA Return On Investment



Return On Investment ADMA's Ranking
Within: No.
Industry # 7
Sector # 39
Overall # 175

Return On Investment Statistics
High Average Low
57.87 %
-48.57 %
-186.97 %
(Dec 31 2024)   (Sep 30 2013)



  News about Adma Biologics Inc Return on Investment ROI

Navigating Double Currents ADMA Biologics Financial Gains and Legal Scrutiny,

October 15, 2024

Investigation of ADMA Biologics Underway Amidst Company’s Financial Milestones In recent developments, ADMA Biologics Inc. a biopharmaceutical company headquartered in New Jersey and listed on NASDAQ under the ticker ADMA, has come under scrutiny from the law firm Bronstein, Gewirtz and Grossman, LLC. The firm announced on October 15, 2024, that it is investigating potential claims on behalf of investors who have purchased securities from ADMA Biologics. This legal investigation aims to explore whether there have been any mishandlings or breaches of fiduciary duty that shareholders ought to be aware of.Investors who have placed their stakes in ADMA Biologics are being encouraged to reach out to the firm to provide pertinent information and possibly participate in the investigation. Additional details can be found on their official website, underlining the importance of transparency and investor protection in financial undertakings.

ADMA Biologics Makes Headway in Debt Reduction and Financial Performance Amidst Recent Challenges,

August 14, 2024

ADMA Biologics Announces Partial Paydown of Revolving Credit Facility
In a recent press release, ADMA Biologics Inc announced that it has utilized its cash on hand to partially pay down its revolving credit facility with Ares Capital, amounting to $30 million. The company emphasized that this repayment was made with no prepayment penalties involved.
ADMA Biologics, a biopharmaceutical company that develops and manufactures plasma-based biologics, has been making significant strides in its financial position. The announcement of the partial paydown comes at a time when the company s stock has reached its 52-week high, reflecting positive market sentiment.





Financial Statements
Adma Biologics Inc's II. Quarter Investments $ 643 Millions ADMA's Balance sheet
Adma Biologics Inc's II. Quarter Income $ 38 Millions Quarterly ADMA's Income Statement
ADMA's Income by Division See ADMA's Income by Division


ADMA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 560 423 268 297 238
Y / Y Investment Growth 32.3 % 57.99 % -9.79 % 24.57 % 30 %
Net Income in Millions 147 198 -28 -66 -72
Y / Y Net Income Growth -25.67 % - - - -
Annual Return On Investment 26.24 % 46.7 % -10.54 % -22.19 % -30.05 %


Annual Roi Comment
In the fiscal year 2025 ROI decreased relative to the previous year to 26.24 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ADMA's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ADMA's Competitors
Subscribers only: Roi for Adma Biologics Inc's Suppliers
Subscribers only: Return On Investment for ADMA's Customers

Other Ratios
ADMA's Roa ADMA's Inventory Turnover Ratio ADMA's Growth Rates ADMA's Dividend Statistics
ADMA's Profitability Ratios ADMA's Asset Turnover Ratio ADMA's Dividend Growth
ADMA's Roe ADMA's Valuation Ratios ADMA's Financial Strength Ratios ADMA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %
Tg Therapeutics Inc   39.26 %
Medpace Holdings Inc   35.54 %
Mettler toledo International Inc   34.41 %
Eli Lilly And Company  33.95 %
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %

Date modified: 2026-09-11T09:50:09+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.